I'm a biotech executive and scientist with a passion for advancing oncology therapeutics from discovery through clinical development. Over the course of my career, I’ve led R\&D strategy and operations in organizations ranging from early-stage startups to large global pharma, including Takeda, ImmunoGen, Novartis, and Biogen. I’ve had the privilege of building high-performing teams, guiding complex portfolios, and contributing to therapies that make a real difference for patients. Today, I enjoy advising innovative biotech companies and VCs as they shape the next generation of cancer treatments.

After nearly three decades of experience across the pharmaceutical and life sciences industries, I’m proud to share my executive biography. From commercial launches to global partnerships, keynote speaking, and team leadership, I’ve been fortunate to work with some incredible people and companies, all driven by a common mission: improving lives through innovative medicine.

I'm excited to share my professional biography, capturing the journey I've taken across HEOR, pharmaceutical innovation, real-world evidence, and health policy. With over 20 years of experience in building value through data, strategic insight, and collaborative leadership, I'm proud to continue this work alongside inspiring teams and partners.

As a physician-scientist and biotech executive, I have dedicated my career to bridging the gap between groundbreaking medical research and commercial success. From securing multimillion-dollar funding to leading strategic M&A deals, my passion lies in driving healthcare innovation that delivers real-world impact. Here is my biography.

Eric Trac is a visionary healthcare investor and biopharmaceutical strategist with a unique blend of medical expertise and financial acumen, driving transformative growth in the healthcare sector. As a Senior Analyst & Director at Sarissa Capital Management, he leads activist investment strategies, evaluates public and private market opportunities, and serves as a board director at Lyndra Therapeutics. With a background in venture capital at Vida Ventures and Vivo Capital, he has played a pivotal role in high-impact transactions, including Bayer’s $4 billion acquisition of AskBio and Centessa Pharmaceuticals’ $250 million Series A. Trac’s deep scientific foundation stems from his MD and MBA from Stanford University and his research in biotechnology at MIT, where he graduated in the top 8% of his class. Recognized as one of *Business Insider’s* “14 Most Impressive Students at MIT,” he continues to leverage his expertise in medicine and finance to drive innovation, maximize shareholder value, and advance the future of biopharmaceuticals.

The healthcare investment landscape is undergoing a revolutionary transformation, addressing the binary risk and inefficiency that have long plagued therapeutic R&D. Traditional drug development processes are slow, costly, and fraught with failure, but advances in AI are now enabling faster, more accurate drug discovery and validation. Leveraging this potential, a novel funding model has emerged, combining insurance underwriting by Lloyd’s of London and non-dilutive lending, supported by AI-driven validation technology from GATC Health. This approach reduces risk for all stakeholders, accelerates funding timelines, and maximizes the chances of success for biotech startups. With nearly 100 startups already in the pipeline, this innovative funding vehicle promises to expedite therapeutic breakthroughs, benefiting investors, companies, and most importantly, patients in need.